Drugs / DBI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05491603 | Nov 2023 | tinea unguium | DermBiont, Inc. | Suspended | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05493488 Comparator | Sep 2022 → Dec 2023 | tinea pedis | DermBiont, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05253755 Comparator | Oct 2021 → Sep 2022 | atopic eczema | DermBiont, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DBI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05491603 ↗ |
| Route | Topical | “Topical application of DBI-001 gel on skin affected with atopic dermatitis.” NCT05253755 ↗ |